Björn Andersson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Björn Andersson has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Diana Swolin-Eide
Department of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
4 shared publications - Per Magnusson
Department of Clinical Chemistry, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden
4 shared publications - Gunnel Hellgren
Department of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
2 shared publications - Kerstin Albertsson-Wikland
Department of Physiology/Endocrinology, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, 40530 Gothenburg, Sweden
2 shared publications - Alessia Capraro
Department of Pharmacology, Institute of Neuroscience and Physiology, University of Gothenburg, 41390 Gothenburg, Sweden
1 shared publication - Andreas Fm Nierop
Department of Physiology/Endocrinology, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
1 shared publication
Latest Publications
- Open Access
- 7 October 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (19) , 8899
Progesterone Modulates Protein Synthesis in Osteoarthritic Fibroblast-like Synoviocytes
Knee osteoarthritis (OA) is highly prevalent in women and is characterized by structural joint alterations and synovial inflammatory processes that contribute to pain and impaired mobility. In a previous study, we identified a positive correlation between progesterone levels and pain intensity in postmenopausal women. However, the role of progesterone in synovial inflammation remains poorly understood. Therefore, this study aimed to characterize sex-specific differences in synovial tissue between postmenopausal women and age-matched men and to investigate the association between progesterone levels and the identified molecular profile. Whole blood and synovial tissue were collected from women and men with knee OA to assess plasma progesterone concentrations and the proteomic profiles of synovial tissue and isolated primary fibroblast-like synoviocytes (FLSs). The expression and localization of progesterone receptors were evaluated using RNAscope and immunofluorescence. FLS stimulated with physiological concentrations of progesterone were used for de novo protein synthesis assays. Quantitative proteomics of synovial tissue revealed enrichment of protein synthesis-related pathways in women compared to age-matched men, and isolated FLS from women with knee OA exhibited a pro-inflammatory and pro-fibrotic proteomic profile. Stratification by plasma progesterone levels identified two distinct patient groups, where lower progesterone levels were associated with pro-inflammatory signatures. The RNAscope analysis demonstrated increased transcriptional activity in synovial tissue from women with knee OA, localized to CD90+ sublining FLS. However, progesterone receptor expression at both the RNA and protein levels showed no sex-specific differences. Moreover, physiological concentrations of progesterone inhibited de novo protein synthesis in FLS isolated from men with knee OA. These findings underscore the hormonal context-dependent modulatory effects of progesterone on synovial inflammation and fibroblast activity. The study further highlights the importance of incorporating sex-specific hormonal profiles into OA patient stratification to support more precise and targeted therapeutic strategies.
- 7 October 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (19) , 8899
Open AccessProgesterone Modulates Protein Synthesis in Osteoarthritic Fibroblast-like Synoviocytes
Knee osteoarthritis (OA) is highly prevalent in women and is characterized by structural joint alterations and synovial inflammatory processes that contribute to pain and impaired mobility. In a previous study, we identified a positive correlation between progesterone levels and pain intensity in postmenopausal women. However, the role of progesterone in synovial inflammation remains poorly understood. Therefore, this study aimed to characterize sex-specific differences in synovial tissue between postmenopausal women and age-matched men and to investigate the association between progesterone levels and the identified molecular profile. Whole blood and synovial tissue were collected from women and men with knee OA to assess plasma progesterone concentrations and the proteomic profiles of synovial tissue and isolated primary fibroblast-like synoviocytes (FLSs). The expression and localization of progesterone receptors were evaluated using RNAscope and immunofluorescence. FLS stimulated with physiological concentrations of progesterone were used for de novo protein synthesis assays. Quantitative proteomics of synovial tissue revealed enrichment of protein synthesis-related pathways in women compared to age-matched men, and isolated FLS from women with knee OA exhibited a pro-inflammatory and pro-fibrotic proteomic profile. Stratification by plasma progesterone levels identified two distinct patient groups, where lower progesterone levels were associated with pro-inflammatory signatures. The RNAscope analysis demonstrated increased transcriptional activity in synovial tissue from women with knee OA, localized to CD90+ sublining FLS. However, progesterone receptor expression at both the RNA and protein levels showed no sex-specific differences. Moreover, physiological concentrations of progesterone inhibited de novo protein synthesis in FLS isolated from men with knee OA. These findings underscore the hormonal context-dependent modulatory effects of progesterone on synovial inflammation and fibroblast activity. The study further highlights the importance of incorporating sex-specific hormonal profiles into OA patient stratification to support more precise and targeted therapeutic strategies.
- Open Access
- 10 June 2022
- Published by Wolters Kluwer Health in Stroke
- Vol. 53 (9) , 2847-2858
Longitudinal Study Reveals Long-Term Proinflammatory Proteomic Signature After Ischemic Stroke Across Subtypes
Background: Inflammation contributes both to the pathogenesis of stroke and the response to brain injury. We aimed to identify proteins reflecting the acute-phase response and proteins more likely to reflect proinflammatory processes present before stroke by broadly profiling inflammation-related plasma proteins in a longitudinal ischemic stroke study. Methods: Participants were from a Swedish ischemic stroke cohort (SAHLSIS [Sahlgrenska Academy Study on Ischemic Stroke], n=600 cases and n=600 controls). Plasma levels of 65 proteins including chemokines, interleukins, surface molecules, and immune receptors were measured once in controls and at 3× in cases: during the acute phase, after 3 months, and for a subgroup (n=223) at 7-year follow-up. Associations between proteins and ischemic stroke or subtype were investigated in multivariable binary regression models corrected for age, sex, vascular risk factors, and multiple testing. Results: In the acute phase, 48 proteins were significantly and independently associated with ischemic stroke (false discovery rate adjusted P <0.05). At 3-month follow-up, 51 proteins and at 7-year follow-up 50 proteins were associated with ischemic stroke. The majority of proteins were upregulated in cases compared with controls (n=34 at all time points) and the most upregulated were CXCL5 (CXC chemokine ligand 5) and OSM (oncostatin M). Generally, large artery and cardioembolic stroke had the highest protein levels. However, several interesting subtype-specific differences were also detected at each time point. Conclusions: We found inflammation-related proteins that were differentially regulated in ischemic stroke cases compared with controls only in the acute phase and others that remained elevated also at later time points. This latter group of proteins could reflect underlying pathophysiological processes of relevance. Future studies both in terms of disease risk and prognostication are warranted.
- 10 June 2022
- Published by Wolters Kluwer Health in Stroke
- Vol. 53 (9) , 2847-2858
Open AccessLongitudinal Study Reveals Long-Term Proinflammatory Proteomic Signature After Ischemic Stroke Across Subtypes
Background: Inflammation contributes both to the pathogenesis of stroke and the response to brain injury. We aimed to identify proteins reflecting the acute-phase response and proteins more likely to reflect proinflammatory processes present before stroke by broadly profiling inflammation-related plasma proteins in a longitudinal ischemic stroke study. Methods: Participants were from a Swedish ischemic stroke cohort (SAHLSIS [Sahlgrenska Academy Study on Ischemic Stroke], n=600 cases and n=600 controls). Plasma levels of 65 proteins including chemokines, interleukins, surface molecules, and immune receptors were measured once in controls and at 3× in cases: during the acute phase, after 3 months, and for a subgroup (n=223) at 7-year follow-up. Associations between proteins and ischemic stroke or subtype were investigated in multivariable binary regression models corrected for age, sex, vascular risk factors, and multiple testing. Results: In the acute phase, 48 proteins were significantly and independently associated with ischemic stroke (false discovery rate adjusted P <0.05). At 3-month follow-up, 51 proteins and at 7-year follow-up 50 proteins were associated with ischemic stroke. The majority of proteins were upregulated in cases compared with controls (n=34 at all time points) and the most upregulated were CXCL5 (CXC chemokine ligand 5) and OSM (oncostatin M). Generally, large artery and cardioembolic stroke had the highest protein levels. However, several interesting subtype-specific differences were also detected at each time point. Conclusions: We found inflammation-related proteins that were differentially regulated in ischemic stroke cases compared with controls only in the acute phase and others that remained elevated also at later time points. This latter group of proteins could reflect underlying pathophysiological processes of relevance. Future studies both in terms of disease risk and prognostication are warranted.
- 10 July 2019
- Published by Taylor & Francis
- p. 82-96
Young people’s appropriation of public space
Young people are often visible actors in the streets and squares of cities. The appropriation of urban public space is one way for youth to take part in city life, and this chapter discusses such participatory processes from a spatial perspective. It discusses the notions of public space and public sphere. The chapter aims to develop further spatial concepts in order to go beyond the public-private dichotomy that is inherent in the conceptions. It focuses on the concepts of front and backstage as well as invited and popular spaces. The chapter focuses on three distinct but not necessarily exclusive modes of appropriation that were identified in various case studies and that are at the heart of social construction processes of public space: voice, sociability and activity. The link to participation lies in the activity; the ‘voice’ is in the doing.
- 10 July 2019
- Published by Taylor & Francis
- p. 82-96
Young people’s appropriation of public space
Young people are often visible actors in the streets and squares of cities. The appropriation of urban public space is one way for youth to take part in city life, and this chapter discusses such participatory processes from a spatial perspective. It discusses the notions of public space and public sphere. The chapter aims to develop further spatial concepts in order to go beyond the public-private dichotomy that is inherent in the conceptions. It focuses on the concepts of front and backstage as well as invited and popular spaces. The chapter focuses on three distinct but not necessarily exclusive modes of appropriation that were identified in various case studies and that are at the heart of social construction processes of public space: voice, sociability and activity. The link to participation lies in the activity; the ‘voice’ is in the doing.
- 1 June 2018
- Published by Elsevier in Growth Hormone & IGF Research
- Vol. 40, 61-68
Broad variability in pharmacokinetics of GH following rhGH injections in children
- 1 June 2018
- Published by Elsevier in Growth Hormone & IGF Research
- Vol. 40, 61-68
Broad variability in pharmacokinetics of GH following rhGH injections in children
- 9 August 2015
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 38 (12) , 1309-1317
Seasonal variations in vitamin D in relation to growth in short prepubertal children before and during first year growth hormone treatment
This study investigated the relationship between seasonal variations in 25-hydroxyvitamin D (25(OH)D) levels and growth in prepubertal children during both the pretreatment year and the first year of GH treatment. The study included 249 short prepubertal children with a broad range of GH secretion, GHmax during a 24 h profile median 23; range 1–127 mU/L, 191 boys (mean age ± SD, 8.6 ± 2.6 years), 58 girls (7.5 ± 1.9 years) receiving GH treatment (mean 43 µg/kg/day; range 17–99 µg/kg/day). Serum 25(OH)D was measured using an automated IDS-iSYS immunoassay. 25(OH)D levels showed seasonal variation, and decreased significantly during GH treatment. 25(OH)D levels at start and first year reduction in 25(OH)D, correlated (−) with the first year growth response during treatment. The degree of GH secretion capacity within our study population of mainly non-GH deficient children and 25(OH)D sufficient (67 ± 29 nmol/L) had no influence on 25(OH)D levels. Growth during GH treatment were independent of seasonal variations in 25(OH)D. Multiple regression analysis showed that 25(OH)D levels at treatment start, together with auxological data and IGF-binding protein-3SDS, explained 61 % of the variation in first year gain in heightSDS. 25(OH)D levels were associated with first year growth response to GH and may be a useful contribution to future growth prediction models.
- 9 August 2015
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 38 (12) , 1309-1317
Seasonal variations in vitamin D in relation to growth in short prepubertal children before and during first year growth hormone treatment
This study investigated the relationship between seasonal variations in 25-hydroxyvitamin D (25(OH)D) levels and growth in prepubertal children during both the pretreatment year and the first year of GH treatment. The study included 249 short prepubertal children with a broad range of GH secretion, GHmax during a 24 h profile median 23; range 1–127 mU/L, 191 boys (mean age ± SD, 8.6 ± 2.6 years), 58 girls (7.5 ± 1.9 years) receiving GH treatment (mean 43 µg/kg/day; range 17–99 µg/kg/day). Serum 25(OH)D was measured using an automated IDS-iSYS immunoassay. 25(OH)D levels showed seasonal variation, and decreased significantly during GH treatment. 25(OH)D levels at start and first year reduction in 25(OH)D, correlated (−) with the first year growth response during treatment. The degree of GH secretion capacity within our study population of mainly non-GH deficient children and 25(OH)D sufficient (67 ± 29 nmol/L) had no influence on 25(OH)D levels. Growth during GH treatment were independent of seasonal variations in 25(OH)D. Multiple regression analysis showed that 25(OH)D levels at treatment start, together with auxological data and IGF-binding protein-3SDS, explained 61 % of the variation in first year gain in heightSDS. 25(OH)D levels were associated with first year growth response to GH and may be a useful contribution to future growth prediction models.
- 25 June 2014
- Published by Wiley in Clinical Endocrinology
- Vol. 82 (1) , 91-99
Short‐term changes in bone formation markers following growth hormone (GH) treatment in short prepubertal children with a broad range of GH secretion
Summary: Objectives: Growth hormone (GH) promotes longitudinal growth and bone modelling/remodelling. This study investigated the relationship between levels of bone formation markers and growth during GH treatment in prepubertal children with widely ranging GH secretion levels.Methods: The study group comprised 113 short prepubertal children (mean age ± SD, 9·37 ± 2·13 years; 99 boys) on GH treatment (33·0 ± 0·06 μg/kg/day) for 1 year. Blood samples were taken at baseline and 1 and 2 weeks, 1 and 3 months, and 1 year after treatment start. Intact amino‐terminal propeptide of type I procollagen (PINP), bone‐specific alkaline phosphatase (BALP) and osteocalcin were measured using an automated IDS‐iSYS immunoassay system.Results: Intact amino‐terminal propeptide of type I procollagen (PINP), BALP and osteocalcin, increased in the short‐term during GH treatment. PINP after 1 week (P = 0·00077), and BALP and osteocalcin after 1 month (P < 0·0001 and P = 0·0043, respectively). PINP levels at 1 and 3 months correlated positively, and osteocalcin levels at 1 week and percentage change after 1 month correlated negatively, with first year growth response. No significant correlations were found between BALP and first year growth. Multiple regression analysis showed that bone marker levels together with auxological data and insulin‐like growth factor binding protein‐3 explained the variation in first year growth response to 36% at start, 32% after 2 weeks and 48% at 3 months.Conclusion: Short‐term increases in levels of the bone formation markers PINP, BALP and osteocalcin showed different temporal patterns, but all correlated with first year growth response during GH treatment. These markers may be a useful addition to existing prediction models for growth response.
- 25 June 2014
- Published by Wiley in Clinical Endocrinology
- Vol. 82 (1) , 91-99
Short‐term changes in bone formation markers following growth hormone (GH) treatment in short prepubertal children with a broad range of GH secretion
Summary: Objectives: Growth hormone (GH) promotes longitudinal growth and bone modelling/remodelling. This study investigated the relationship between levels of bone formation markers and growth during GH treatment in prepubertal children with widely ranging GH secretion levels.Methods: The study group comprised 113 short prepubertal children (mean age ± SD, 9·37 ± 2·13 years; 99 boys) on GH treatment (33·0 ± 0·06 μg/kg/day) for 1 year. Blood samples were taken at baseline and 1 and 2 weeks, 1 and 3 months, and 1 year after treatment start. Intact amino‐terminal propeptide of type I procollagen (PINP), bone‐specific alkaline phosphatase (BALP) and osteocalcin were measured using an automated IDS‐iSYS immunoassay system.Results: Intact amino‐terminal propeptide of type I procollagen (PINP), BALP and osteocalcin, increased in the short‐term during GH treatment. PINP after 1 week (P = 0·00077), and BALP and osteocalcin after 1 month (P < 0·0001 and P = 0·0043, respectively). PINP levels at 1 and 3 months correlated positively, and osteocalcin levels at 1 week and percentage change after 1 month correlated negatively, with first year growth response. No significant correlations were found between BALP and first year growth. Multiple regression analysis showed that bone marker levels together with auxological data and insulin‐like growth factor binding protein‐3 explained the variation in first year growth response to 36% at start, 32% after 2 weeks and 48% at 3 months.Conclusion: Short‐term increases in levels of the bone formation markers PINP, BALP and osteocalcin showed different temporal patterns, but all correlated with first year growth response during GH treatment. These markers may be a useful addition to existing prediction models for growth response.
- Open Access
- 1 January 2008
- Published by Springer Nature in Proteome Science
- Vol. 6 (1) , 35
A proteomic approach identified growth hormone-dependent nutrition markers in children with idiopathic short stature
The broad range in growth observed in short prepubertal children receiving the same growth hormone (GH) dose is due to individual variation in GH responsiveness. This study used a pharmaco-proteomic approach in order to identify novel biomarkers that discriminate between short non-GH-deficient (GHD) children who show a good or poor growth response to GH treatment.
- 1 January 2008
- Published by Springer Nature in Proteome Science
- Vol. 6 (1) , 35
Open AccessA proteomic approach identified growth hormone-dependent nutrition markers in children with idiopathic short stature
The broad range in growth observed in short prepubertal children receiving the same growth hormone (GH) dose is due to individual variation in GH responsiveness. This study used a pharmaco-proteomic approach in order to identify novel biomarkers that discriminate between short non-GH-deficient (GHD) children who show a good or poor growth response to GH treatment.